Browse recruiting and upcoming clinical trials for atypical hemolytic uremic syndrome.
Patient-friendly, AI-assisted summaries based on official ClinicalTrials.gov ↗ records. Last updated: Oct 10, 2026
About this list Hide ClinicalTrials.gov is the complete and most up-to-date source. Trials may be missing, and trial information may have changed since our last check. Always verify important information in the official registry.
Sex All Female (includes ALL) Male (includes ALL) All sexes only
Age All ages Pediatric (under 18) Adult (18+)
Clear Who can join AI Adults (≥18 years) with a clinical diagnosis of atypical hemolytic uremic syndrome (aHUS) who meet specific blood and kidney criteria.
What is being studied AI Tests ravulizumab's effects on platelet counts and kidney function over 26 weeks.
Study type Treatment (drug) · Phase 4
Who can join AI Adults (18–100) with atypical hemolytic uremic syndrome (aHUS) who are switching from anti‑C5 antibody therapy.
What is being studied AI Tests switching from anti-C5 antibody to iptacopan for aHUS
Study type Treatment (drug) · Phase 3
Countries China, France, Germany +5
Who can join AI Adults (18–100) with atypical hemolytic uremic syndrome (aHUS) who completed a prior Novartis iptacopan Phase 3 aHUS trial.
What is being studied AI Tests long-term safety, tolerability, and efficacy of iptacopan in aHUS.
Study type Treatment (drug) · Phase 3
Countries Brazil, China, Czechia +3
Who can join AI Adults hospitalized with hypertensive emergency–associated hemolytic uremic syndrome (HE‑aHUS) and severe acute kidney injury.
What is being studied AI Compares early eculizumab plus blood-pressure control with blood-pressure control alone on kidney outcomes.
Study type Treatment (drug) · Phase 3
Who can join AI Adults (18–65) with atypical hemolytic uremic syndrome (aHUS) and evidence of ongoing thrombotic microangiopathy.
What is being studied AI Tests whether IV NM8074 induces remission of thrombotic microangiopathy in aHUS patients.
Study type Treatment (drug) · Phase 2
Who can join AI People with certain rare kidney diseases, patients with early-onset undiagnosed genetic disorders (WES-negative), and healthy adult volunteers.
What is being studied AI Uses RNA sequencing of cultured skin fibroblasts to detect altered RNA expression and splicing.
Who can join AI Children and people with atypical hemolytic uremic syndrome (aHUS).
What is being studied AI Creates patient iPSC-derived endothelial cells to study function and screen drugs in the lab.
Who can join AI People with atypical hemolytic uremic syndrome (aHUS) treated with ravulizumab under the National Drug Program who agree to participate.
What is being studied AI Collects medical history and prospective follow-up data on aHUS patients treated with ravulizumab.
Who can join AI Females who are pregnant, postpartum, or breastfeeding and were exposed to Ultomiris, including those with PNH, aHUS, gMG, or NMOSD.
What is being studied AI Collects pregnancy, maternal, fetal and infant outcome data after Ultomiris exposure.
Countries Australia, France, Germany +4
Who can join AI Children and people with one of the many rare kidney diseases listed in this registry.
What is being studied AI Collects clinical data, patient-reported outcomes, and samples to support research.
Who can join AI Adults (18+) with thrombotic microangiopathy (including atypical hemolytic uremic syndrome) documented by blood tests or kidney biopsy.
What is being studied AI Evaluates HMEC endothelial test and ex vivo C5b9 to identify complement-driven TMA.
Who can join AI People with rare or undiagnosed conditions, and unaffected carriers of rare or uncommon diseases.
What is being studied AI Collects patients' contact, demographic, and health information for a centralized rare-disease registry.
Countries Australia, United States
Who can join AI People of any age diagnosed with atypical hemolytic-uremic syndrome (aHUS), treated or untreated.
What is being studied AI Collects post-marketing safety and disease-progression data for patients with aHUS.
Countries Australia, Belgium, Canada +14